Urologic Oncology: Seminars and Original Investigations
Volume 27, Issue 5 , Pages 496-501, September 2009

Phase II study of intravesical therapy with AD32 in patients with papillary urothelial carcinoma or carcinoma in situ (CIS) refractory to prior therapy with bacillus Calmette-Guerin (E3897): A trial of the Eastern Cooperative Oncology Group☆

  • Jeffrey M. Ignatoff, M.D., F.A.C.S.

      Affiliations

    • Northwestern University-Feinberg School of Medicine, Chicago, IL 60611, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1-912-598-0651; fax: +1-912-598-0651
    • ,
  • Yu-Hui Chen, M.Ph., M.S.

      Affiliations

    • Dana Farber Cancer Institute, Boston, MA 02115, USA
    • ,
  • Richard Evan Greenberg, M.D.

      Affiliations

    • Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    • ,
  • Julio M. Pow-Sang, M.D.

      Affiliations

    • Moffitt Cancer Center, Tampa, FL 33612, USA
    • ,
  • Edward M. Messing, M.D.

      Affiliations

    • University of Rochester, Rochester, NY 14627, USA
    • ,
  • George Wilding, M.D.

      Affiliations

    • University of Wisconsin, Madison, WI 53706, USA

Received 8 February 2008; received in revised form 11 May 2008; accepted 13 May 2008. published online 22 July 2008.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

☆ This study was conducted by the Eastern Cooperative Oncology Group (Robert L. Comis, M.D.) and supported in part by Public Health Service grants CA23318, CA66636, CA21115, CA27525, CA11083, CA17145, CA21076 and from the National Cancer Institute, National Institutes of Health and the Department of Health and Human Services. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the National Cancer Institute.

PII: S1078-1439(08)00116-6

doi:10.1016/j.urolonc.2008.05.004

Urologic Oncology: Seminars and Original Investigations
Volume 27, Issue 5 , Pages 496-501, September 2009

Article Tools